Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
FRLN Stock Summary
In the News
Freeline (FRLN) Shares Rise on Merger Agreement With Syncona
Freeline Therapeutics (FRLN) is set to be acquired by Syncona Ltd. The transaction is expected to be closed in the first quarter of 2024.
Freeline Therapeutics to Host Second Quarter 2023 Financial Results Call
LONDON, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, August 15, 2023 to report its second quarter financial results and provide a corporate update.
Freeline to Participate in Upcoming Investor Conferences
LONDON, July 31, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that the company will be participating in two upcoming investor conferences in August. Details are as follows:
New Strong Buy Stocks for July 14
LE, ING, PD, FRLN and SUNW have been added to the Zacks Rank #1 (Strong Buy) List on July 14, 2023.
Freeline Therapeutics Holdings PLC Sponsored ADR (FRLN) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Freeline Therapeutics Holdings PLC Sponsored ADR (FRLN) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Freeline to Present at 2023 Jefferies Healthcare Conference
LONDON, June 02, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that its Chief Executive Officer Michael Parini will present at the 2023 Jefferies Healthcare Conference being held in New York on June 7-9, 2023.
Freeline to Present at 22nd Annual Needham Virtual Healthcare Conference
LONDON, April 12, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that its Chief Executive Officer Michael Parini will present at the 22nd Annual Needham Virtual Healthcare Conference being held on April 17-20, 2023.
Freeline to Present at the Stifel Healthcare Conference
LONDON, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that Chief Executive Officer Michael Parini will participate in a fireside chat at the Stifel Healthcare Conference being held in New York.
5 Biotech Stocks Likely to Outpace Q2 Earnings Estimates
Let us look at some drug/biotech stocks, ABSI, AXLA, FRLN, DICE and PLRX, which are poised to beat on second-quarter earnings.
Freeline Posts Cases Of Lower FIX Expression, Higher Liver Enzymes From Hemophilia Candidate
Freeline Therapeutics Holdings plc (NASDAQ: FRLN) announced the presentation of safety and initial efficacy data from the first cohort of the Phase 1/2 B-LIEVE trial for FLT180a for hemophilia B. As of the data cut-off of May 23, 2022, a one-time FLT180a dose of 7.7e11 vg/kg.
FRLN Financial details
FRLN Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -78.65 | -127.39 | -102.09 | -58.98 | -22.52 | |
Operating cash flow per share | -60.9 | -123.64 | -100.65 | -45.19 | -19.8 | |
Free cash flow per share | -69.76 | -130.78 | -103.31 | -46.98 | -21.57 | |
Cash per share | 37.93 | 174.16 | 243.74 | 49.43 | 11.96 | |
Book value per share | 54.28 | 200.75 | 264.75 | 50.6 | 13.26 | |
Tangible book value per share | 54.28 | 200.75 | 264.73 | 50.6 | 13.26 | |
Share holders equity per share | 54.28 | 200.75 | 264.75 | 50.6 | 13.26 | |
Interest debt per share | 0.36 | 0 | 0 | 0 | -1.11 | |
Market cap | 114.26M | 114.26M | 258.43M | 70.69M | 28.17M | |
Enterprise value | 98.21M | 40.56M | 28.46M | -46.97M | -13.18M | |
P/E ratio | -3.43 | -2.12 | -2.68 | -0.5 | -0.32 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -4.43 | -2.18 | -2.72 | -0.66 | -0.36 | |
PFCF ratio | -3.87 | -2.06 | -2.65 | -0.63 | -0.33 | |
P/B Ratio | 4.97 | 1.34 | 1.03 | 0.59 | 0.54 | |
PTB ratio | 4.97 | 1.34 | 1.03 | 0.59 | 0.54 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -3.06 | -0.79 | -0.33 | 0.35 | 0.14 | |
EV to operating cash flow | -3.81 | -0.78 | -0.3 | 0.44 | 0.17 | |
EV to free cash flow | -3.33 | -0.73 | -0.29 | 0.42 | 0.15 | |
Earnings yield | -0.29 | -0.47 | -0.37 | -1.99 | -3.16 | |
Free cash flow yield | -0.26 | -0.48 | -0.38 | -1.58 | -3.03 | |
Debt to equity | 0 | 0 | 0 | 0 | 0.11 | |
Debt to assets | 0 | 0 | 0 | 0 | 0.07 | |
Net debt to EBITDA | 0.5 | 1.43 | 2.7 | 0.88 | 0.43 | |
Current ratio | 2.85 | 7.16 | 13.72 | 6.2 | 2.18 | |
Interest coverage | -271.4 | 0 | 0 | 0 | 9.55 | |
Income quality | 0.77 | 0.97 | 0.99 | 0.77 | 0.88 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | -0.02 | |
Capex to operating cash flow | 0.15 | 0.06 | 0.03 | 0.04 | 0.09 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | -3.86 | -1.96 | -1.31 | -1.79 | -4.03 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 309.93 | 758.55 | 779.83 | 259.13 | 81.98 | |
ROIC | -1.79 | -0.75 | -0.41 | -1.19 | -1.54 | |
Return on tangible assets | -1.04 | -0.55 | -0.36 | -0.99 | -1.01 | |
Graham Net | 32.94 | 166.16 | 238.24 | 42.79 | 5.77 | |
Working capital | 16.93M | 76.61M | 239.36M | 107.61M | 36.66M | |
Tangible asset value | 22.93M | 84.91M | 249.78M | 120.43M | 53.74M | |
Net current asset value | 16.93M | 76.61M | 239.36M | 107.61M | 33.4M | |
Invested capital | 0 | 0 | 0 | 0 | 0.11 | |
Average receivables | 0 | 10.25M | 13.81M | 9.16M | 1.72M | |
Average payables | 0 | 3.72M | 6.96M | 6.64M | 7.62M | |
Average inventory | 0 | 729K | 1.96M | 4.75M | 12.03M | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 1.37K | 1.53K | 792.25 | 2.11K | |
Days of inventory on hand | 0 | 198.74 | 583.13 | 980.27 | 3.7K | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0.27 | 0.24 | 0.46 | 0.17 | |
Inventory turnover | 0 | 1.84 | 0.63 | 0.37 | 0.1 | |
ROE | -1.45 | -0.63 | -0.39 | -1.17 | -1.7 | |
Capex per share | -8.86 | -7.14 | -2.66 | -1.8 | -1.78 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0.14 | 0 | |
Net income per share | -3.44 | -5.31 | 0.27 | -3.69 | -2.77 | |
Operating cash flow per share | -3.5 | -4.59 | -4.25 | -3.98 | -1.99 | |
Free cash flow per share | -4 | -5.49 | -4.34 | -4.04 | -1.99 | |
Cash per share | 15.2 | 10.92 | 12.76 | 8.93 | 6.76 | |
Book value per share | 15.83 | 12.11 | 12.89 | 9.67 | 6.89 | |
Tangible book value per share | 15.83 | 12.11 | 12.89 | 9.67 | 6.89 | |
Share holders equity per share | 15.83 | 12.11 | 12.89 | 9.67 | 6.89 | |
Interest debt per share | 2.83 | 2.84 | -7.78 | 1.1 | 0.92 | |
Market cap | 45.49M | 30.86M | 29.66M | 11.21M | 18.74M | |
Enterprise value | -8.4M | -10.49M | -20.37M | -22.79M | -6.72M | |
P/E ratio | -0.76 | -0.34 | 6.36 | -0.17 | -0.39 | |
Price to sales ratio | 0 | 0 | 0 | 18.16 | 3.75K | |
POCF ratio | -3 | -1.55 | -1.61 | -0.65 | -2.16 | |
PFCF ratio | -2.62 | -1.3 | -1.57 | -0.64 | -2.16 | |
P/B Ratio | 0.66 | 0.59 | 0.53 | 0.27 | 0.62 | |
PTB ratio | 0.66 | 0.59 | 0.53 | 0.27 | 0.62 | |
EV to sales | 0 | 0 | 0 | -36.94 | -1.34K | |
Enterprise value over EBITDA | 0.37 | 0.65 | 0.54 | 1.19 | 0.58 | |
EV to operating cash flow | 0.55 | 0.53 | 1.1 | 1.32 | 0.78 | |
EV to free cash flow | 0.48 | 0.44 | 1.08 | 1.3 | 0.77 | |
Earnings yield | -0.33 | -0.75 | 0.04 | -1.43 | -0.65 | |
Free cash flow yield | -0.38 | -0.77 | -0.64 | -1.56 | -0.46 | |
Debt to equity | 0.17 | 0.11 | 0.1 | 0.11 | 0.13 | |
Debt to assets | 0.12 | 0.07 | 0.07 | 0.08 | 0.08 | |
Net debt to EBITDA | 2.39 | 2.58 | 1.33 | 1.78 | 2.2 | |
Current ratio | 3.31 | 2.18 | 2.81 | 2.45 | 1.95 | |
Interest coverage | -79.42 | -3.11 | 0.51 | 0 | 0 | |
Income quality | 1.02 | 0.86 | -15.82 | 1.08 | 0.72 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 15.39 | 1.28K | |
Research and developement to revenue | 0 | 0 | 0 | 14.31 | 1.16K | |
Intangibles to total assets | 0 | -0.02 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.14 | 0.2 | 0.02 | 0.01 | 0 | |
Capex to revenue | 0 | 0 | 0 | -0.41 | -1.2 | |
Capex to depreciation | -5.36 | -12.37 | -1.23 | -0.59 | -0.02 | |
Stock based compensation to revenue | 0 | 0 | 0 | 1.74 | 179 | |
Graham number | 34.99 | 38.05 | 8.83 | 28.33 | 20.74 | |
ROIC | -0.25 | -0.31 | -0.26 | -0.3 | -0.32 | |
Return on tangible assets | -0.15 | -0.26 | 0.01 | -0.26 | -0.25 | |
Graham Net | 8.91 | 5.27 | 7.62 | 4.84 | 2.93 | |
Working capital | 51.69M | 36.66M | 41.13M | 27.13M | 16.52M | |
Tangible asset value | 68.58M | 53.74M | 55.99M | 42.02M | 30.04M | |
Net current asset value | 42.61M | 33.4M | 38.49M | 25.18M | 14.82M | |
Invested capital | 0.17 | 0.11 | 0.1 | 0.11 | 0.13 | |
Average receivables | 2.81M | 2.1M | 1.38M | 2.32M | 2.97M | |
Average payables | 8.92M | 10.01M | 11.26M | 9.66M | 7.33M | |
Average inventory | 3.09M | 10.84M | 10.71M | 2.42M | 914.5K | |
Days sales outstanding | 0 | 0 | 0 | 454.96 | 50.81K | |
Days payables outstanding | 2.23K | 2.85K | 3.47K | 1.42K | 1.82K | |
Days of inventory on hand | 904.16 | 5K | 1.05K | 219.82 | 180.11 | |
Receivables turnover | 0 | 0 | 0 | 0.2 | 0 | |
Payables turnover | 0.04 | 0.03 | 0.03 | 0.06 | 0.05 | |
Inventory turnover | 0.1 | 0.02 | 0.09 | 0.41 | 0.5 | |
ROE | -0.22 | -0.44 | 0.02 | -0.38 | -0.4 | |
Capex per share | -0.5 | -0.9 | -0.09 | -0.06 | 0 |
FRLN Frequently Asked Questions
What is Freeline Therapeutics Holdings plc stock symbol ?
Freeline Therapeutics Holdings plc is a GB stock and trading under the symbol FRLN
What is Freeline Therapeutics Holdings plc stock quote today ?
Freeline Therapeutics Holdings plc stock price is $6.49 today.
Is Freeline Therapeutics Holdings plc stock public?
Yes, Freeline Therapeutics Holdings plc is a publicly traded company.